207results about How to "Prevent fibrosis" patented technology

Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The pouches of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use, and, optionally, include one or more drugs in the polymer matrix of the coating to provide prophylactic effects and/or alleviate side effects or complications associated with the surgery or implantation of the CRM or other implantable medical device.

Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device and preventing or retarding the formation of a biofilm.

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein the anti-angiogenic activity of the composition is separate from the vascular leakage inhibiting activity of the composition. The animal experiencing at least one of vascular leakage, inflammation and fibrosis has a disease selected from the group consisting of diabetes, chronic inflammation, brain edema, arthritis, uvietis, macular edema, cancer, hyperglycemia, a kidney inflammatory disease, a disorder resulting in kidney fibrosis, a disorder of the kidney resulting in proteinuria, and combinations thereof. The composition capable of inhibiting at least one of vascular leakage, inflammation and fibrosis is selected from the group consisting of angiostatin, fragments of angiostatin, analogs or derivatives of angiostatin, kringle 5 of plasminogen, fragments of kringle 5 of plasminogen, analogs or derivatives of kringle 5 of plasminogen, pigment epithelium-derived factor, fragments of pigment epithelium-derived factor, analogs or derivatives of pigment epithelium-derived factor and combinations thereof.

This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.

The present invention concerns a new process for depositing a thick compact layer of biomolecules for instance such a layer with thickness in the μm scale and, for depositing a thick compact layer of cells in the μm scale. The deposited layer is made by application of an unbalanced (asymmetrical) alternating voltage polarization between two electrodes to a dissolved biomolecule or cell from low conductivity solutions. The process allows the rapid manufacturing of sensors and the coating of devices with functional cells and biomolecules. Examples are provided on the preparation of functional sensors such as a glucose, a lactose sensor, a hydrogen peroxide sensor and a glutamate sensor. Examples are also provided on the deposition of eukaryoric cells such as saccharomyces cerevisiae. The examples demonstrate a process that can be applied to coat devices with biomolecules and biological cells.

The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.

The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or α-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

The invention discloses a nerve conduit and a preparation method thereof. The nerve conduit comprises an inner layer, a transition layer, an outer layer and at least one cavity used for storing a bioactive factor solution, wherein the outer surface of the inner layer is sequentially coated with the transition layer and the outer layer; the cavity is positioned between the inner surface of the outer layer and the outer surface of the transition layer and/or between the outer surface of the inner layer and the inner surface of the transition layer; the inner layer is a hydrophilic cytoskeleton layer made by adopting an electrostatic spinning method; and the outer layer is a hydrophobic nerve conduit scaffold layer made by adopting the electrostatic spinning method. The nerve conduit can be used for loading bioactive factors before an operation in a required mode, such as injection, soaking and the like due to the miniature cavity, so that the production quality of the product is easy to control, the survival rate of the bioactive factor can be greatly improved, the nerve regeneration can be promoted in high efficiency, and the nerve repairing effect can be reinforced.

Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The pouches of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use, and, optionally, include one or more drugs in the polymer matrix of the coating to provide prophylactic effects and/or alleviate side effects or complications associated with the surgery or implantation of the CRM or other implantable medical device.

Composition for preventing the formation of new scar, e.g. myofibroblast, having BMP-7 polypeptide is disclosed. The composition for preventing the formation of scar includes an effective amount of BMP-7 (Bone Morphogenic Protein-7) polypeptide of sequence 1. The effective amount is 50 ng/ml-50 μg/ml or 0.1 ng-1 μg/kg by weight and the scar is a corneal scar.

The invention belongs to the field of biological medicine, and relates to application of micromolecular polypeptide KP-6, in particular to application of micromolecular polypeptide KP-6 in preparing a drug for treating a chronic kidney disease (CKD). An amino acid sequence of the polypeptide KP-6 is shown as SEQ ID NO. 1. The micromolecular polypeptide KP-6 has a significant effect of inhibiting kidney tissue fibrosis and CKD development, has no obvious toxic or side effects, and therefore can be used for preparing the drug for effectively treating the chronic kidney disease.

Wound repair materials and methods of using the same to inhibit excess fibrosis are disclosed.

An oral dilator includes a first body, a second body, a rotary member, and a positioning member. The first body includes a housing and a first duckbilled element. The second body includes a second duckbilled element corresponding to the first duckbilled element. The rotary member drives the second body to rotate. The positioning member is on the first body and selectively locks or unlocks the relative position between the first duckbilled element and the second duckbilled element when the second duckbilled element is driven to rotate by the rotary member.

The invention relates to a novel application of a micro-molecule polypeptide KP-1, and in particular to an application of the micro-molecule polypeptide KP-1 in preparing a medicine for treating chronic kidney diseases (CKD). The invention provides the application of the KP-1 in treating the CKD; and the KP-1 is obvious in curative effect and is free from obvious toxic and side effects. Therefore,the KP-1 provided by the invention can be used for preparing a pharmaceutical preparation for treating the CKD.

The present invention provides compositions, formulations and methods for treating liver diseases related to tissue inflammation and progressive fibrosis, e.g., progressive liver fibrosis following either chronic or acute injury. The compositions of the invention provide the use of therapeutic agents as an adjunct therapy to transplantation of cell populations capable of effecting liver repair.

The invention provides a PPS (polyphenylene sulfide) and nano Al2O3 filled PTFE (polytetrafluoroethylene) composite material. PPS and nano Al2O3 filled PTFE composite material samples are prepared with a method comprising steps of mechanical blending, cold press molding and sintering; frictional wear performance of the samples under the dry friction condition is tested by an MRH3 type ring-block tester; an SEM (scanning electron microscope) is adopted for observing and analyzing morphology of the wear surface and the transfer membrane surface of each sample. When the mass fraction of PPS is 5%, the friction coefficient and volume abrasion rate of the PPS/PTFE composite material both reach the minimum value; with addition of nano Al2O3, the tribological property of the PPS/PTFE composite material is further improved, when the mass fraction of nano Al2O3 is 5%, the volume abrasion rate of the nano Al2O3/PPS/PTFE composite material is the minimum, and wear resistance is increased by 276 times as compared with that of pure PTFE. The main wear mechanism of PTFE/PPS/PTFE and the nano Al2O3/PPS/PTFE composite material is adhesion wear at the room temperature, and the nano Al2O3/PPS/PTFE composite material is accompanied with abrasive wear at 150 DEG C.

The invention belongs to the technical field of high polymer materials, and particularly relates to filling modified polytetrafluoroethylene and a preparation method thereof. The filling modified polytetrafluoroethylene provided by the invention is prepared from resonance mixed powder through curing, mould pressing extrusion, calendering, extrusion aid removal and stretching puffing; and the resonance mixed powder comprises the following components: polytetrafluoroethylene resin, carbon nanotubes, a fluorine-containing silane coupling agent and an extrusion aid. A resonance mixing technology is adopted to replace traditional high-speed mixing, so that fibration of polytetrafluoroethylene resin in the mixing process is avoided, and the puffing performance of the polytetrafluoroethylene resin-based material is improved; meanwhile, the fluorine-containing silane coupling agent is added, so that the interfacial compatibility of the carbon nanotubes and the polytetrafluoroethylene is remarkably improved, and the dispersion uniformity of the carbon nanotubes in the polytetrafluoroethylene is improved; and on the basis, a tensile expansion technology is combined to prepare the filling modified polytetrafluoroethylene material with high conductivity, high mechanical strength and low density.

The invention relates to Sedum aizoon L. tea, which is prepared by using the following raw materials in percentage by weight: 70 to 85 percent of Sedum aizoon L. leaves, 11 to 30 percent of aloe leaves, 3 to 15 percent of ginseng leaves and 3 to 15 percent of folium cortex eucommiae, optimally 76 percent of Sedum aizoon L. leaves, 18 percent of aloe leaves, 3 percent of ginseng leaves and 3 percent of folium cortex eucommiae. Sitosterol in the Sedum aizoon L. tea can prevent the cholesterol absorption of human bodies, reduce blood fat and prevent angiosclerosis; flavones in the Sedum aizoon L. tea can expand blood vessels, promote blood circulation and reduce myocardial oxygen consumption; and oleanolic acid in the Sedum aizoon L. tea can protect liver tissues and prevent liver fibrosis. The Sedum aizoon L. tea can be drunk for a long time for strengthening body, preventing arteriosclerosis and heart diseases, protecting the liver and delaying aging.